A new analysis by U.S. Pharmacopeia reveals that nearly 700 U.S. medicines rely on at least one chemical sourced solely from China, exposing a critical vulnerability in the drug supply chain.
700 U.S. Medicine Rely on China
Widely used treatments—including antibiotics like amoxicillin and generics for heart disease, cancer, and HIV—depend on Chinese raw materials, which are cheaper to produce due to fewer environmental restrictions. Experts warn that escalating tensions between Washington and Beijing, or future pandemics, could disrupt exports and jeopardize patient access.
President Donald Trump has proposed a 100% tariff on Chinese goods, raising concerns about cost hikes for drugmakers. While major pharmaceutical companies are investing in U.S. manufacturing, these facilities won’t produce raw materials.
The analysis underscores the lack of financial incentive to shift early-stage production back to the U.S. and calls for better data to guide resilience strategies. Even drugs with global manufacturing footprints remain tethered to China at their earliest stages.
Follow us on:
Read More News at #latestmalaysia #BusinessNews and #WorldFuture
